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Abstract
Background: Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous
immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%.
In spite of its effectiveness, some children do not respond to this therapy and still develop coronary aneurysms (CAA).
The optimal treatment for IVIG non-responsive patients remains controversial although corticoids have been
suggested to be an effective treatment in some patients. For those patients still resistant to IVIG and corticoids,
interleukin-1 receptor antagonists (IL-1RA) such anakinra could be an alternative.
Case presentation: We present a 3 year-old Caucasian patient with KD without cardiac complications but with
important resistance to treatment. After becoming resistant to IVIG and corticoids, anakinra proved to be an
effective treatment.
Conclusions: To our knowledge, this is the first report of the utility of IL-1RA in refractory KD without coronary
impairment. The patient fulfilled the classical criteria for KD and, after becoming resistant to first and second line
treatments, anakinra proved to be an effective treatment. Further studies are required to determine if this is an
effective treatment option for other cases of resistant Kawasaki disease.
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Background
KD is an acute self-limited systemic vasculitis of un-
known etiology presenting predominantly in toddlers
and children under 5 years old. Diagnosis is based on
clinical criteria including fever, exanthema, conjunctiv-
itis, changes in hands and feet, erythema of oral mucosa
and lips and cervical lymphadenopathy. Prognosis
depends on the extent of cardiac involvement; CAA
develop in 20-25% of untreated patients and these may
lead to myocardial infarction and sudden death if proper
treatment with IVIG is not administered within the first
10 days of illness [1, 2]. Early treatment with IVIG
decreases the risk of cardiac complications to less than
5%. In spite of its effectiveness, some children do not
respond to this therapy and still develop CAA. Although
the optimal treatment for IVIG non-responsive patients
remains controversial, adding steroids to the 2nd IVIG
dose has proven to be effective to reduce the incidence
of CAA and improve the prognosis of resistant KD when
administered in patients fulfilling IVIG resistance criteria
in the Kobayashi scoring system [3, 4]. For those who
present a lack of response to this 2nd step of treatment,
other approaches have been described, such as inflixi-
mab [5], plasma exchange [6] or cyclosporine [7]. In the
last years some reports have suggested the role of
IL-1RA in the treatment of severe or resistant cases of
KD [8, 9]. We present a case of a IVIG and steroids
resistant KD successfully treated with IL-1RA (anakinra).
Case presentation
We present a previously healthy 3 year-old Caucasian
girl, who was admitted with persistent fever for 5 days,
generalized rash, non-purulent conjunctivitis, labial and
lingual erythema and swollen feet. On admission, the girl
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had significant irritability. Blood tests showed normal
hemoglobin, white blood cells and platelets, high C-
reactive protein (CRP - 14 mg/dL) and high transami-
nases (AST 168 U/L, ALT 86 U/L). Fulfilling the KD
classical criteria, KD was diagnosed and treatment with
IVIG (2 g/kg) and aspirin (100 mg/kg) was initiated.
Echocardiography two days after admission showed mild
mitral and tricuspideal regurgitation but no CAA. Elec-
trocardiogram was normal.
Despite the initial IVIG treatment, fever, rash, conjunc-
tivitis and labial and lingual erythema remained, and 2
additional IVIG doses and 2 metilprednisolone (30 mg/kg)
pulses were administered in the subsequent days. Eight
days after admission, fever disappeared and analytical
features normalized.
Maintenance treatment with oral prednisone (0.5 mg/
kg/day) was initiated but, on day 11 after admission, fever
recurred with important irritability, exanthema and hand
and feet desquamation. An important increase on CRP
(16.5 mg/dL), ESR (126 mm/h) and platelets (808000)
was registered and there was a decrease in hemoglobin
(7.5 g/dL) (Fig. 1). Echocardiography did not show
changes. Another 2 metilprednisolone pulses were ad-
ministered without response. On day 14 after admission
(19 days since onset), due to conventional treatment
failure and having ruled out, together with the patient’s
parents, the use of other intravenous treatments such as
infliximab, IL-1RA was initiated (anakinra - 2 mg/kg
subcutaneous once a day for 14 days). Fever and irrit-
ability disappeared within hours and CRP, ESR, platelets
and hemoglobin became normal in the subsequent blood
tests (24 h and 5 days after treatment initiation).
Six days after anakinra was initiated the patient was
discharged. Treatment was maintained for 2 weeks com-
bined with aspirin. No relapses appeared after anakinra
discontinuation and subsequent blood tests and echocar-
diographies at weeks 2, 8 and 16 after discharge were
normal (no changes on coronary arteries sizes have been
recorded over time and z-scores have maintained between
1 and 1.5 SDs). The patient did not experience any side ef-
fects or complications during or after the use of anakinra.
Discussion
In the last years, some studies have suggested an important
role for interleukin 1 (IL-1) in the pathogenesis of KD [10].
Genome-Wide Association Studies (GWAS) have also
found functional SNPs in ITPKC and CASP3 genes that
are associated with an increased risk of unresponsiveness
to IVIG therapy [11]. Lee et al. suggested, using a mouse
model of KD, that IL-1 receptor-deficient mice were pro-
tected from induced coronary lesions. Furthermore, daily
injections of the IL-1RA prevented induced coronary le-
sions in normal mice [12].
Another study developed in a cohort of Taiwanese
children with KD, found a significant increase in IVIG
resistance risk in those patients with the IL-1B −511 TT
and IL-1B −31 CC genotypes and the diplotype TC/TC
in the IL-1 family of genes [13]. These results suggest an
important genetic association between IL-1 and failure
of initial IVIG therapy and support the previous findings
that IL-1 secretion is associated with IVIG treatment in
KD [14, 15].
Anakinra is a recombinant antagonist of the IL-1 re-
ceptor used successfully to treat systemic onset juvenile
idiopathic arthritis. Regarding the clinical application of
the exposed findings on the role of IL-1 in the pathogen-
esis of KD, two clinical trials are being held in Europe
and the USA and two case reports on KD patients
treated with anti-Il-1 have been reported [8, 9]. Both
papers describe severe cases of KD, one of them compli-
cated with a macrophage activation syndrome (MAS),
that were resistant to multiple IVIG and prednisolone
pulses and improved drastically after the administration
of anakinra with analytical normalization and complete
reversal of the echocardiogram changes. We present a
case report in which the patient fulfilled the classical cri-
teria for KD but had no cardiac or severe complications
and, after becoming resistant to first and second line
Fig. 1 Time course of C reactive protein (CRP), platelets and treatment
Sánchez-Manubens et al. BMC Pediatrics  (2017) 17:102 Page 2 of 3
treatments, IL-1R blockade proved to be an effective
treatment. Further studies are required and are being
held to determine if this is an effective treatment option
for all cases of resistant Kawasaki disease.
Conclusion
To our knowledge, this is the first report on the utility
of IL-1RA in refractory KD without coronary impairment
or MAS. The patient fulfilled the classical criteria for KD
and, after becoming resistant to first and second line treat-
ments, IL-1R blockade proved to be an effective treatment
without side effects or complications. Further studies are
required to determine if this is an effective treatment op-
tion for other cases of resistant Kawasaki disease.
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